Evidence map›Paper›PMID 42211128›Full record

ArticleiScience2026

LDLRAD2 drives glycolysis and angiogenesis to promote extramedullary infiltration in acute myeloid leukemia.

Kexin Jin, Yang Zhao, Qiang Guo, Jingyi Lin, Hongli Zhao, Shengjin Fan, Chuiming Jia, Shuchuan Liu, Desheng Kong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kexin JinDepartment of Hematology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin 150006, China.
Yang ZhaoDepartment of Hematology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin 150006, China.
Qiang GuoDepartment of Hematology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin 150006, China.
Jingyi LinDepartment of Hematology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin 150006, China.
Hongli ZhaoDepartment of Hematology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin 150006, China.
Shengjin FanDepartment of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Chuiming JiaHematology Department, Harbin Medical University Cancer Hospital, Harbin 150081, China.
Shuchuan LiuDepartment of Hematology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin 150006, China.
Desheng KongDepartment of Hematology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin 150006, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) remodels the bone marrow microenvironment and can spread to extramedullary sites, a feature associated with adverse clinical outcomes. Here, we identify low-density lipoprotein receptor class A domain-containing 2 (LDLRAD2) as a driver of extramedullary infiltration (EMI) through analyses of patient samples, public datasets, AML cell models, and xenografts. LDLRAD2 increased glucose consumption, lactate production, endothelial tube formation, spleen infiltration, and microvascular density, whereas its knockdown reduced these phenotypes. Mechanistically, LDLRAD2 interacted with metadherin (MTDH) and activated PI3K/AKT/mTOR signaling, thereby promoting glycolysis, angiogenesis, and EMI. Inhibition of LDLRAD2 or treatment with 2-deoxyglucose suppressed glycolysis-associated angiogenic effects. These findings support LDLRAD2-associated metabolic and angiogenic remodeling as a mechanism underlying EMI in AML and highlight a potential therapeutic vulnerability.

Indexed as

BiochemistryHealth sciencesPathology

Identifiers

PMID42211128
PMCPMC13214308

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.